ClinicalTrials.gg
CompletedNCT00508469Updated Jul 12, 2012Results posted

Adherence Assessment With Travalert Dosing Aid

A Phase 4 interventional study of Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) and Travoprost 0.004% eye drops in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-12.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
25th of 45
102 · median 135
Started
2007
with 4 others
Phase 4
22 of 46
2 open now
Registered
11th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 25th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 4, and was the 11th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension

Keywords

  • Intraocular pressure
  • Open-angle glaucoma
  • Ocular hypertension
  • Adherence
  • Compliance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of open-angle glaucoma or ocular hypertension;
  • Inadequate control with beta-blocker or prostaglandin monotherapy and starting therapy with travoprost 0.004% and timolol 0.05%;
  • Intraocular pressure (IOP) at the screening visit in at least one eye ≥ 19 mmHg but not exceeding 36 mmHg in either eye;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Females of currently pregnant, breastfeeding, or not taking control measures to prevent pregnancy;
  • Not currently receiving treatment for lowering IOP with beta-blockers or prostaglandin analogs;
  • Currently on therapy or was in therapy with another agent within 30 days prior to the baseline visit;
  • History of chronic or recurrent severe inflammatory eye disease, or history of ocular trauma within the past six (6) months, or history of ocular infection or ocular inflammation within the past three (3) months in either eye;
  • History of or progressive retinal disease or history of any other severe ocular pathology in either eye that would preclude the administration of a topical prostaglandin analogue;
  • History of severe or serious to prostaglandin drugs or their analogues, to topical or systemic beta-blockers, or to any components of the study medication;
  • Intraocular surgery within the past six (6) months or ocular laser surgery within the past three (3) months as determined by patient history and/or examination in either eye;
  • Any abnormality preventing reliable applanation tonometry of either eye;
  • Best-corrected visual acuity worse than 20/30 Snellen in either eye;
  • Use of any additional topical or systemic ocular hyposensitive medication during the study;
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Travalert with travoprost/timolol fixed combination

    One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

    Drug: Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) · Device: Travalert Dosing Aid

  • Experimental
    Travalert with travoprost and timolol

    One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.

    Drug: Travoprost 0.004% eye drops · Drug: Timolol 0.05% eye drops · Device: Travalert Dosing Aid

Interventions

  • DrugTravoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)

    Drug page: Travoprost

    One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

    Also known as: DuoTrav®

  • One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

  • One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.

  • DeviceTravalert Dosing Aid

    Approved device used with study medication to record time of instillation and quantify dosing

06

What researchers measure

Primary outcomes

  1. Adherence

    Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.

    Time frame: 6 months

07

Results

Posted Jul 12, 2012

Participant flow

Patients were recruited from 5 hospitals in Spain.

Participant flow — Overall Study
MilestoneTravalert With Travoprost/Timolol Fixed CombinationTravalert With Travoprost and Timolol
Started5250
Completed3540
Not completed1710

Outcome measures

PrimaryAdherence

Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.

Time frame:
6 months
Reported as:
Number · percentage of adherent patients
Adherence
percentage of adherent patientsTravalert With Travoprost/Timolol Fixed CombinationTravalert With Travoprost and Timolol
Adherence6343

Adverse events

Collected over Adverse events were collected for the duration of the study: 2 years, 3 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travalert With Travoprost/Timolol Fixed Combination—1/52 (1.9%)0/52 (0%)
Travalert With Travoprost and Timolol—1/50 (2%)0/50 (0%)
Most frequent serious events
Most frequent serious events
EventTravalert With Travoprost/Timolol Fixed CombinationTravalert With Travoprost and Timolol
BrachycardiaCardiac disorders0/521/50
Heart FailureCardiac disorders1/520/50

Baseline characteristics

Age Continuous
Age Continuous(years)Travalert With Travoprost/Timolol Fixed CombinationTravalert With Travoprost and TimololTotal
Mean63.8 ± 11.168.6 ± 11.866.2 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Travalert With Travoprost/Timolol Fixed CombinationTravalert With Travoprost and TimololTotal
Female262551
Male171734
08

Study locations

1 site
  • Zaragoza
    Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 30, 2007
Start
Oct 2007
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Jul 12, 2012
Last update
Jul 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00508469
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jul 30, 2007
Start date
Oct 2007
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Jul 12, 2012
Last update
Jul 12, 2012

Study contacts

Dr Francisco M. Honrubia
study director · Independent

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Travoprost · Timolol

Start the discussion